T-Regulatory Cells
Jan 31, 2025
Interleukin-2-targeting Therapies: Journey from Bench to Bedside
Expected data readouts in 2025, filling the unmet need, and estimated market opportunity in Oncology, Immunological and Neurodegenerative Diseases In the evolving landscape of immunotherapy, Interleukin-2 (IL-2) therapies have carved a niche, particularly in the treatment of metastatic melanoma, metastatic renal...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
